---
date: "2024-01-09 16:39:37" # 2021-07-14
title: "Precision BioSciences (DTIL) Soars on Licensing Agreement with TG Therapeutics (TGTX)"
# image: "images/plots/{{titleSlag}}.png"
author: "justin-guese"
draft: false
---
tickers: <a href='https://finance.yahoo.com/quote/DTIL' target='_blank'>DTIL</a>, <a href='https://finance.yahoo.com/quote/TGTX' target='_blank'>TGTX</a> 

source: <a href='https://www.benzinga.com/news/24/01/36559781/why-precision-biosciences-stock-is-up-today' target='_blank'>Benzinga</a>

#### tickers affected by this

| ticker | polarity | why? |
|------------|------------|------------|
| DTIL | positively | The licensing agreement with TG Therapeutics provides Precision BioSciences with a significant upfront payment and potential future milestone payments, which could positively impact the company's financial position. Additionally, the collaboration expands the utility of Precision BioSciences' allogeneic CAR T assets into the immunology field, potentially opening up new opportunities for growth and development. |
| TGTX | positively | The licensing agreement with Precision BioSciences provides TG Therapeutics with additional revenue potential and expands their development pipeline, which could positively impact the ticker TGTX. |



#### our strategies and bots using these tickers

None so far...

## summary

# Precision BioSciences Signs Licensing Agreement with TG Therapeutics, Inc.

Precision BioSciences, Inc. (DTIL) shares are trading higher on Tuesday after the company announced a licensing agreement with TG Therapeutics, Inc. (TGTX). The agreement grants Precision BioSciences an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases.

Under the terms of the agreement, Precision BioSciences will receive $17.5 million in upfront and near-term payments, with the potential for up to $288 million in future development milestone payments. The company is excited to extend the utility of its allogeneic CAR T assets into immunology through this collaboration with TG Therapeutics.

Michael Amoroso, CEO of Precision BioSciences, stated, "We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases. Key factors in our decision to partner with the TG team include their recent development, regulatory and commercial successes in the multiple sclerosis space, which we believe are strong indicators of the commitment and expertise they will bring to the development of azer-cel in autoimmune diseases."

Following the announcement, Precision BioSciences shares experienced heavy trading volume, with more than 26 million shares already traded in the session. This far exceeds the stock's 100-day average volume of 938,000 shares.

As of the time of publication, Precision BioSciences shares are up 9% at 43 cents.

This article is for informational purposes only and does not constitute investment advice.